[Rinsho ketsueki] The Japanese journal of clinical hematology最新文献_第2页

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2026-01-01 DOI: 10.11406/rinketsu.67.1026

引用次数: 0

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2026-01-01 DOI: 10.11406/rinketsu.67.1020

引用次数: 0

[Aplastic anemia developed after treatment with durvalumab]. 【durvalumab治疗后出现再生障碍性贫血】。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2026-01-01 DOI: 10.11406/rinketsu.67.896

Kaho Maeshima, Yo Sakayori, Hiroki Yokoyama, Atsushi Katsube, Kazuhito Suzuki, Hiroto Ishii, Susumu Tanoue, Hideki Uryu, Daiki Hattori, Yasutaka Mochizuki, Shingo Yano

{"title":"[Aplastic anemia developed after treatment with durvalumab].","authors":"Kaho Maeshima, Yo Sakayori, Hiroki Yokoyama, Atsushi Katsube, Kazuhito Suzuki, Hiroto Ishii, Susumu Tanoue, Hideki Uryu, Daiki Hattori, Yasutaka Mochizuki, Shingo Yano","doi":"10.11406/rinketsu.67.896","DOIUrl":"https://doi.org/10.11406/rinketsu.67.896","url":null,"abstract":"A 76-year-old woman with stage IIIB squamous cell lung carcinoma developed pancytopenia following maintenance therapy with durvalumab. She was diagnosed with squamous cell lung carcinoma (T4N2M0, stageIIIB) in December 2023. Following a favorable response to chemoradiotherapy, maintenance therapy with durvalumab was initiated in June 2024. Thrombocytopenia was observed starting in August, and platelet count had decreased to 22,000/µl in October, leading to the discontinuation of durvalumab. However, the condition progressed to pancytopenia. Bone marrow biopsy revealed hypocellular marrow without dysplasia, fibrosis, or hemophagocytosis. Additional findings included paroxysmal nocturnal hemoglobinuria-type blood cells and fatty marrow replacement on spinal MRI. Based on these comprehensive findings, the patient was diagnosed with aplastic anemia (AA) in January 2025. Immunosuppressive therapy combining antithymocyte globulin, cyclosporine A, and eltrombopag was initiated in February 2025, resulting in a favorable response. AA is a relatively rare immune-related adverse event, and reports of AA induced by durvalumab are extremely limited. This case highlights the importance of considering AA in the differential diagnosis of persistent thrombocytopenia or pancytopenia during immune checkpoint inhibitor therapy.","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"67 8","pages":"896-901"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148860653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Chronic-phase chronic myeloid leukemia complicated by dasatinib-associated lymphadenopathy]. [慢性粒细胞白血病合并达沙替尼相关淋巴结病]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2026-01-01 DOI: 10.11406/rinketsu.67.923

Kiho Tozuka, Risa Nishiyama, Takahiro Shibayama, Toshiya Kagoo, Hironori Ueno, Junichi Shiraishi, Naoya Nakamura, Akihiro Yokoyama

{"title":"[Chronic-phase chronic myeloid leukemia complicated by dasatinib-associated lymphadenopathy].","authors":"Kiho Tozuka, Risa Nishiyama, Takahiro Shibayama, Toshiya Kagoo, Hironori Ueno, Junichi Shiraishi, Naoya Nakamura, Akihiro Yokoyama","doi":"10.11406/rinketsu.67.923","DOIUrl":"https://doi.org/10.11406/rinketsu.67.923","url":null,"abstract":"A 55-year-old man was diagnosed with chronic myeloid leukemia (CML) in the chronic phase and achieved a major molecular response (MMR) 3 months after dasatinib induction. Seven months later, he noticed left cervical lymphadenopathy, and 18-fluorodeoxyglucose positron emission tomography (FDG-PET) showed marked 18F-FDG uptake at the left cervical and supraclavicular lymph nodes. Left cervical lymph node biopsy showed reactive follicular hyperplasia and increased numbers of large B-cells between the follicles. Based on the clinical course, dasatinib-associated lymphadenopathy (DAL) was diagnosed. The treatment was switched to bosutinib, and lymph node enlargement resolved after 4 weeks. Lymphoproliferative disorder during CML treatment is a rare adverse event of dasatinib and is classified in the category of immune deficiency and dysregulation-associated LPDs (IDD-LPDs) in the WHO Classification of Tumours, 5th Edition. As more new drugs associated with IDD-LPDs are used across various indications, the scope of iatrogenic immune deficiency-related LPDs continues to broaden. Although the pathogenesis of DAL remains unclear, the immune dysregulation mechanisms of dasatinib may contribute. Since spontaneous remission can be expected with dasatinib discontinuation, observation should be considered even when differentiation from de novo lymphoma is difficult, and the decision to initiate chemotherapy should be made carefully.","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"67 8","pages":"923-928"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148860720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Comparison of peripheral neuropathy between Pola-R-CHP and R-CHOP: a retrospective analysis in an ambulatory therapy center]. [Pola-R-CHP和R-CHOP治疗周围神经病变的比较：一个门诊治疗中心的回顾性分析]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2026-01-01 DOI: 10.11406/rinketsu.67.879

Kabuto Kuhara, Riko Suzuki, Takayuki Ozawa, Moe Okada, Ayano Esaki, Toru Kida, Hiroaki Masaie, Satoru Kosugi

{"title":"[Comparison of peripheral neuropathy between Pola-R-CHP and R-CHOP: a retrospective analysis in an ambulatory therapy center].","authors":"Kabuto Kuhara, Riko Suzuki, Takayuki Ozawa, Moe Okada, Ayano Esaki, Toru Kida, Hiroaki Masaie, Satoru Kosugi","doi":"10.11406/rinketsu.67.879","DOIUrl":"https://doi.org/10.11406/rinketsu.67.879","url":null,"abstract":"Pola-R-CHP is becoming a standard therapy for DLBCL. We retrospectively compared the incidence of chemotherapy-induced peripheral neuropathy (CIPN)-related events (numbness and constipation) assessed by the nursing staff at our ambulatory therapy center (ATC) between these two regimens. Patients with DLBCL who received the 2nd (or 3rd) to 6th cycle of either regimen at ATC from Jan 2020 to Dec 2024 were analyzed. Twenty-six patients received Pola-R-CHP, and 35 received R-CHOP. Whereas 92% of patients treated with Pola-R-CHP received 100% of the planned polatuzumab dose, only 58% of those treated with R-CHOP received 100% of the planned vincristine dose. The incidence of numbness increased with the number of cycles and was more frequent with R-CHOP than with Pola-R-CHOP. The difference was most significant at the 4th cycle. In contrast, the incidence of constipation was comparable between the two regimens. Pola-R-CHP may be associated with a lower incidence of CIPN compared with R-CHOP. The high percentage of patients receiving the planned doses of polatuzumab further indicates that Pola-R-CHP could achieve better dose intensity with a lower risk of CIPN.","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"67 8","pages":"879-884"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148860717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Current diagnosis and treatment of congenital platelet function disorders: focus on Glanzmann thrombasthenia and Bernard-Soulier syndrome]. 【先天性血小板功能障碍的诊断和治疗现状：以Glanzmann血栓减少症和Bernard-Soulier综合征为重点】。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2026-01-01 DOI: 10.11406/rinketsu.67.584

Hirokazu Kashiwagi

{"title":"[Current diagnosis and treatment of congenital platelet function disorders: focus on Glanzmann thrombasthenia and Bernard-Soulier syndrome].","authors":"Hirokazu Kashiwagi","doi":"10.11406/rinketsu.67.584","DOIUrl":"10.11406/rinketsu.67.584","url":null,"abstract":"Platelet function is regulated by numerous molecules, and congenital abnormalities of these molecules result in a variety of congenital platelet function disorders. Among these, Glanzmann thrombasthenia (GT), caused by a congenital deficiency or molecular abnormality in GPIIb-IIIa (αIIbβ3), and Bernard-Soulier syndrome (BSS), caused by a congenital deficiency or molecular abnormality in the GPIb-IX-V complex, are representative disorders that manifest as severe bleeding tendency from infancy. GT and BSS are diagnosed mainly by flow cytometry of membrane glycoproteins in addition to conventional light transmission aggregometry. Platelet transfusions are indicated for bleeding refractory to standard hemostatic measures, and recombinant factor VIIa (rFVIIa) has been shown to be effective in GT. rFVIIa has conventionally been used in GT patients refractory to platelet transfusion due to alloantibody production, but is now available in Japan regardless of alloantibody status or platelet transfusion refractoriness. rFVIIa should be considered especially in patients at risk of alloantibody production due to platelet transfusion.","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"67 6","pages":"584-591"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148414329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Updates on antiphospholipid syndrome]. [抗磷脂综合征的最新进展]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2026-01-01 DOI: 10.11406/rinketsu.67.592

Yuichiro Fujieda

引用次数: 0

[Improvement of chylothorax after lymphangiography in AL amyloidosis]. [AL淀粉样变性患者经淋巴管造影后乳糜胸的改善]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2026-01-01 DOI: 10.11406/rinketsu.67.684

Yusuke Kiyoki, Marin Sakaki, Yoshiro Chiba, Haruo Ohtani, Shigeru Chiba

引用次数: 0

[Recent advances and future perspectives in the treatment of NK/T-cell lymphoma]. NK/ t细胞淋巴瘤治疗的最新进展及未来展望

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2026-01-01 DOI: 10.11406/rinketsu.67.780

Motoko Yamaguchi

{"title":"[Recent advances and future perspectives in the treatment of NK/T-cell lymphoma].","authors":"Motoko Yamaguchi","doi":"10.11406/rinketsu.67.780","DOIUrl":"https://doi.org/10.11406/rinketsu.67.780","url":null,"abstract":"Extranodal natural killer/T-cell lymphoma (ENKL) is a rare lymphoid malignancy that has historically poor outcomes when treated with conventional lymphoma chemotherapy regimens such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). In the early 2000s, treatment strategies designed to overcome multidrug resistance were adopted. The RT-2/3DeVIC (radiotherapy, dexamethasone, etoposide, ifosfamide, carboplatin) for newly diagnosed localized ENKL and SMILE (dexamethasone, methotrexate, ifosfamide, L-asparaginase, etoposide) chemotherapy for newly diagnosed advanced-stage or relapsed/refractory ENKL, developed through clinical trials, subsequently improved the prognosis of patients with ENKL in real-world clinical practice in Japan. However, two outcome studies have also highlighted the limitations of these approaches. More recently, therapeutic development for ENKL has shifted toward PD-1/PD-L1 inhibitor-based strategies, as well as molecularly targeted therapies informed by advances in basic research. This review summarizes the current treatment landscape for ENKL in Japan, describes therapeutic developments outside Japan and ongoing investigational approaches, and discusses future directions in ENKL treatment development.","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"67 7","pages":"780-785"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148665301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Sustained molecular response after discontinuation of ropeginterferon alfa-2b in a young patient with polycythemia vera]. [一名真性红细胞增多症年轻患者停用ropeg干扰素α -2b后的持续分子反应]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2026-01-01 DOI: 10.11406/rinketsu.67.209

Daigo Akahane, Meiko Kuriyama, Kai Osone, Yuya Arai, Shohei Wakamatsu, Shunsuke Ohtuki, Mitsuru Moriyama, Michiyo Asano, Seiichiro Katagiri, Seiichiro Yoshizawa

{"title":"[Sustained molecular response after discontinuation of ropeginterferon alfa-2b in a young patient with polycythemia vera].","authors":"Daigo Akahane, Meiko Kuriyama, Kai Osone, Yuya Arai, Shohei Wakamatsu, Shunsuke Ohtuki, Mitsuru Moriyama, Michiyo Asano, Seiichiro Katagiri, Seiichiro Yoshizawa","doi":"10.11406/rinketsu.67.209","DOIUrl":"10.11406/rinketsu.67.209","url":null,"abstract":"Ropeginterferon alfa-2b (ropeg-IFN), a treatment that allows for prolonged dosing intervals through site-specific PEGylation, has been approved for the treatment of polycythemia vera (PV) in patients for whom existing therapies are insufficient or unsuitable. In this case report, we describe a woman in her thirties who was treated with ropeg-IFN. Blood tests showed increased levels of all three blood cell lineages, and PV was diagnosed following bone marrow examination. The patient was enrolled in a clinical study in which she received ropeg-IFN because phlebotomy could not be performed due to difficulty with securing peripheral vascular access. Complete hematologic response (CHR) was achieved 12 weeks after the start of administration, and molecular response (MR) with a JAK2 V617F allele burden of <1% was achieved after approximately 156 weeks of continuous administration of ropeg-IFN. Alopecia (grade 1) occurred as an adverse event, but resolved after ropeg-IFN dose reduction. The patient maintained CHR and MR for 2 years following treatment discontinuation. We also discuss the potential benefit of ropeg-IFN in low-risk PV patients who were not previously considered candidates for aggressive cytoreductive therapy.","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"67 3","pages":"209-213"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147576426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0